Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Immune Therapeutics, Inc. (IMUN)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues | | | | | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | | | | 100.0% | 0.0% | 0.0% | 100.0% |
| Gross profit | | | | | 0.0% | 100.0% | 100.0% | 0.0% |
| Selling, general and administrative | | | | | | -3.8% | 62.2% | 261747.2% |
| Research and development | | | | | | | 1.3% | 280552.8% |
| General and administrative | | | | | 73459.5% | | | |
| Depreciation | | | | | | | | |
| EBIT | | | | | -79211.5% | 107.7% | -27.0% | -542300.0% |
| Pre-tax income | | | | | -102305.5% | -104.1% | -37.8% | 1491334.0% |
| Income taxes | | | | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | | | | | -102305.5% | -104.1% | -37.8% | 1491334.0% |
|